<DOC>
	<DOCNO>NCT02276937</DOCNO>
	<brief_summary>DVC1-0101 gene therapy medicine treat peripheral arterial disease ( PAD ) base recombinant F-gene-deleted , non-transmissible Sendai virus ( rSeV/dF ) express human fibroblast growth factor-2 ( FGF-2 ) gene . The previous Phase I/IIa study demonstrate serious adverse event relate administration , suggest possible improvement local blood flow walk performance PAD patient . The primary objective current Phase IIb study investigate clinical efficacy DVC1-0101 ( 1x10^9 ciu/leg , 5x10^9 ciu/leg ) patient IC . We also aim examine dose-response relationship use rate improvement walk function indicator .</brief_summary>
	<brief_title>Randomized Phase IIb Trial DVC1-0101</brief_title>
	<detailed_description />
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Intermittent Claudication</mesh_term>
	<criteria>1 ) Meet criterion ( 1 ) ( 5 ) confirm least 1 specialist qualify Japanese Society Cardiovascular Surgery least 1 specialist qualify Japanese Association Cardiovascular Intervention Therapeutics . 1. arteriosclerosis obliterans stable symptom , intermittent claudication ( ACD &lt; 200 ) able walk treadmill 2. rest anklebrachial pressure index &lt; 0.9 3. refuse revascularization , risk revascularization may great benefit , develop obliteration revascularization 4. angiographic finding show patency abdominal aorta proximal side external iliac artery 5. angiographic finding meet criterion ( 4 ) , stenosis obliteration femoropopliteal region morphology define type C D base TASCII 2 ) Administering cilostazol least 1 month still meet criterion 1 ) . 3 ) Aged 40 year 79 year . 4 ) Either sex , either inpatient outpatient . 5 ) Able give write consent . 1 . Have ischemic ulcer . 2 . Diagnosed Buerger 's disease . 3 . Have current past history lifethreatening allergy . 4 . Have show suspected cancer . 5 . With concurrent proliferative intraocular neovascularization . 6 . With concurrent cardiac failure . 7 . With untreated severe arrhythmia . 8 . Have suspect interstitial pneumonia . 9 . Have progressive hepatic disorder . 10 . Have moderate severe hepatic disorder . ( 1 ) aspartate aminotransferase alanine aminotransferase &gt; 2.5 time upper limit ( 2 ) Prothrombin time 14 second longer ( 3 ) Serum bilirubin &gt; 2.0 time upper limit 11 . Diagnosed hepatic cirrhosis ( classify B C ChildPugh ) . 12 . Have inflammatory disease . 13 . Treated immunosuppressant corticosteroid treatment various inflammatory disease organ transplantation . 14 . Underwent extirpative surgery malignant tumor past 5 year . 15 . Have cerebral hemorrhage cerebral infarction past 6 month . 16 . With blood disease . 17 . With moderate severe renal dysfunction ( CCr &lt; 40 mL/min ) 18 . With alcohol drug dependence . 19 . Pregnant/lactating female , wish suspect pregnant . 20 . Positive HIV antibody . 21 . Took part clinical study research past 30 day . 22 . Not permitted participate study principal investigator subinvestigator reason .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Recombinant Sendai virus</keyword>
	<keyword>fibroblast growth factor-2</keyword>
	<keyword>treadmill</keyword>
</DOC>